VM BioPharma's VM202 granted fast track

Status
Not open for further replies.
Will it cure als?
 
The study that was recently completed was primarily a safety study. Some efficacy data was collected, but it was not powered for that question (at present, even slowing ALS would be enough for a drug to be approved, and is much more likely). The next study (planned as a Phase II/III) will provide more information in that regard.

VM202 is further advanced in diabetic peripheral neuropathy and non-healing foot ulcers (Phase III), which will help it gain approval for ALS if it is effective in this disease.
 
Status
Not open for further replies.
Back
Top